A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with ß-thalassemia major

被引:8
作者
Elalfy, Mohsen S. [1 ]
Massoud, Walid [2 ]
Elsherif, Nayera H. [1 ]
Labib, Jonair H. [1 ]
Elalfy, Omar M. [1 ]
Elaasar, Safaa [3 ]
von Mackensen, Sylvia [4 ]
机构
[1] Ain Shams Univ, Pediat Thalassemia Ctr, Cairo, Egypt
[2] Amer Univ Cairo, Educ Testing & Assessment Div, Cairo, Egypt
[3] Ain Shams Univ, Dept Psychol, Fac Women, Cairo, Egypt
[4] Univ Med Ctr Hamburg Eppendorf UKE, Inst & Policlin Med Psychol Hamburg, Hamburg, Germany
关键词
adherence; ICT-Sat; iron chelators; patient-rated outcome; questionnaire; Thalassemia; QUALITY-OF-LIFE; BETA-THALASSEMIA; CARDIAC IRON; DESFERRIOXAMINE TREATMENT; OVERLOADED PATIENTS; DEFERASIROX; DEFERIPRONE; TRANSFUSION; DEFEROXAMINE; EFFICACY;
D O I
10.1002/pbc.23413
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background High satisfaction with iron chelation is a major determinant for adherence to ICT in beta-thalassaemia major (beta-TM) patients. In this study, a new tool to assess different domains of satisfaction for available forms of ICT was developed and validated. The impact of patients' satisfaction with ICT has been tested. Methods. Items were generated via focus groups and a preliminary version with 24 items (ICT-Sat) with an additional item for treatment preference and a knowledge questionnaire (KQ) was developed. 170 beta-TM patients from three Thalassaemia centers in Egypt, aged 2-32 years received three questionnaires to fill in; the new ICT-Sat, a KQ, and a previously validated tool for satisfaction with ICT (SICT) and retested 4-6 weeks later to ensure re-test reliability. Type of chelation, drug related adverse events, compliance with ICT, and serum ferritin level (SF) during the year prior to the study as well as available cardiac T2*data were recorded. Results. One hundred and fifty two beta-TM patients completed all questionnaires; median age was 12 years. The final 15 remaining ICT-Sat items, yielding to four domain scores, explained 70.6% of the total variance. The "perceived effectiveness" and "fear and worries" domains of the ICT-Sat correlated significantly with the domains "perceived effectiveness" and "acceptance" of the SICT. Patients treated with oral ICT were more satisfied with perceived effectiveness, and their side effects. Conclusions. A new clinically based ICT-Sat tool was developed and revealed good psychometric characteristics. Adherence to ICT was better correlated with "perceived effectiveness" and SF level. Pediatr Blood Cancer 2012; 58: 910-915. (C) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:910 / 915
页数:6
相关论文
共 50 条
  • [41] Hepcidin mutation in a β-thalassemia major patient with persistent severe iron overload despite chelation therapy
    Lorena Duca
    Paola Delbini
    Isabella Nava
    Maria Domenica Cappellini
    Anna Meo
    Internal and Emergency Medicine, 2010, 5 : 83 - 85
  • [42] Hepcidin mutation in a β-thalassemia major patient with persistent severe iron overload despite chelation therapy
    Duca, Lorena
    Delbini, Paola
    Nava, Isabella
    Cappellini, Maria Domenica
    Meo, Anna
    INTERNAL AND EMERGENCY MEDICINE, 2010, 5 (01) : 83 - 85
  • [43] Renal function in β-thalassemia major patients treated with two different iron-chelation regimes
    Osama Tanous
    Yossi Azulay
    Raphael Halevy
    Tal Dujovny
    Neta Swartz
    Raul Colodner
    Ariel Koren
    Carina Levin
    BMC Nephrology, 22
  • [44] Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone
    Lai, Maria Eliana
    Grady, Robert W.
    Vacquer, Stefania
    Pepe, Alessia
    Carta, Maria Paola
    Bina, Patrizio
    Sau, Franco
    Cianciulli, Paolo
    Maggio, Aurelio
    Galanello, Renzo
    Farci, Patrizia
    BLOOD CELLS MOLECULES AND DISEASES, 2010, 45 (02) : 136 - 139
  • [45] Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study
    Enas A Hamed
    Nagla T ElMelegy
    Italian Journal of Pediatrics, 36
  • [46] Continued improvement in myocardial T2☆ over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
    Pennell, Dudley J.
    Porter, John B.
    Cappellini, Maria Domenica
    Chan, Lee Lee
    El-Beshlawy, Amal
    Aydinok, Yesim
    Ibrahim, Hishamshah
    Li, Chi-Kong
    Viprakasit, Vip
    Elalfy, Mohsen Saleh
    Kattamis, Antonis
    Smith, Gillian
    Habr, Dany
    Domokos, Gabor
    Roubert, Bernard
    Taher, Ali
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (01): : 48 - 54
  • [47] EFFECT OF COMBINED CHELATION THERAPY WITH DEFERIPRONE AND DEFEROXAMINE ON LEFT VENTRICULAR DIASTOLIC FUNCTION IN ADULT β-THALASSEMIA MAJOR PATIENTS
    Tsiapras, Dimitrios
    Fragatou, Soso
    Farmaki, Kalistheni
    Kyrzopoulos, Stamatios
    Paraskevaidis, Ioannis
    Voudris, Vasilios
    Kremastinos, Dimitrios
    HEMOGLOBIN, 2010, 34 (03) : 210 - 220
  • [48] Markers of Renal Complications in Beta Thalassemia Patients with Iron Overload Receiving Chelation Agent Therapy: A Systematic Review
    Romadhon, Pradana Zaky
    Ashariati, Ami
    Bintoro, Siprianus Ugroseno Yudho
    Thaha, Mochammad
    Suryantoro, Satriyo Dwi
    Windradi, Choirina
    Mahdi, Bagus Aulia
    Novendrianto, Dwiki
    Widiyastuti, Krisnina Nurul
    Martani, Okla Sekar
    Widiasi, Etha Dini
    Agustin, Esthiningrum Dewi
    Prabowo, Emil
    Putra, Yasjudan Rastrama
    Thahadian, Harik Firman
    Adhikara, Imam Manggalya
    Adyarini, Dwita Dyah
    Prahasanti, Kartika
    Putri, Aditea Etnawati
    Yusoff, Narazah Mohd
    JOURNAL OF BLOOD MEDICINE, 2022, 13 : 725 - 738
  • [49] Dual-echo TFE MRI for the assessment of myocardial iron overload in beta-thalassemia major patients
    Hazirolan, Tuncay
    Eldem, Gonca
    Uenal, Sule
    Akpinar, Burcu
    Guemruek, Fatma
    Alibek, Sedat
    Haliloglu, Mithat
    DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2010, 16 (01) : 59 - 62
  • [50] Combined Chelation Therapy with Deferoxamine and Deferiprone in β-Thalassemia Major: Compliance and Opinions of Young Thalassemic Patients
    Hatzipantelis, Emmanuel S.
    Karasmanis, Konstantinos
    Perifanis, Vassilios
    Vlachaki, Efthimia
    Tziomalos, Konstantinos
    Economou, Marina
    HEMOGLOBIN, 2014, 38 (02) : 111 - 114